Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immunovia AB ( (SE:IMMNOV) ) has provided an update.
Immunovia announced that Dr. Bryson Katona will present at a symposium during the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer conference. The presentation will focus on controversies in pancreatic cancer surveillance guidelines and the potential role of blood-based biomarker testing, which could influence future surveillance practices. This highlights Immunovia’s commitment to advancing early detection methods and its potential impact on pancreatic cancer surveillance.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes blood-based testing to detect proteins and antibodies indicating pancreatic cancer in high-risk individuals. Immunovia collaborates with healthcare providers, experts, and patient advocacy groups to make its tests available, with the USA being the largest market for pancreatic cancer detection.
Average Trading Volume: 13,910,907
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK213.4M
For a thorough assessment of IMMNOV stock, go to TipRanks’ Stock Analysis page.